



THE JOURNAL OF CLINICAL PSYCHIATRY

Supplementary Material

Article Title: Assessment of the Safety, Efficacy, and Practicality of Treatment Algorithms Including Amantadine, Metformin, and Zonisamide for the Prevention of Weight Gain During Treatment With Olanzapine in Outpatients With Schizophrenia

Author(s): Vicki Poole Hoffmann, PharmD; Michael Case, MS; and Jennie G. Jacobson, PhD

DOI Number: 10.4088/JCP.09m05580

List of Supplementary Material for the article

1. [eTable 1](#) Treatment-Emergent Adverse Events Reported in $\geq 5\%$ of Participants in Any Group

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

eTable 1. Treatment-Emergent Adverse Events Reported in $\geq 5\%$ of Participants in Any Group

Treatment-Emergent Adverse Event	OLZ	OLZ/A	OLZ/B	p-value, Fisher's Exact Test		
	(N=50)	(N=76)	(N=73)	OLZ vs. OLZ/A	OLZ vs. OLZ/B	OLZ/A vs. OLZ/B
	n (%)	n (%)	n (%)			
Somnolence	4 (8.0%)	5 (6.6%)	8 (11.0%)	.740	.760	.395
Diarrhea	0	3 (3.9%)	10 (13.7%)	.276	.005	.044
Insomnia	5 (10.0%)	4 (5.3%)	1 (1.4%)	.481	.040	.367
Nausea	2 (4.0%)	3 (3.9%)	5 (6.8%)	1.000	.700	.489
Weight Increased	2 (4.0%)	4 (5.3%)	4 (5.5%)	1.000	1.000	1.000
Akathisia	2 (4.0%)	4 (5.3%)	2 (2.7%)	1.000	1.000	.681
Headache	2 (4.0%)	2 (2.6%)	4 (5.5%)	.649	1.000	.436
Increased Appetite	3 (6.0%)	1 (1.3%)	3 (4.1%)	.300	.686	.360
Dry Mouth	2 (4.0%)	4 (5.3%)	0	1.000	.163	.120
Sedation	0	4 (5.3%)	2 (2.7%)	.151	.514	.681
Vomiting	0	1 (1.3%)	5 (6.8%)	1.000	.079	.112
Nasopharyngitis	0	4 (5.3%)	0	.151	--	.120

Abbreviations: HDL = high-density lipoprotein; LDL = low-density lipoprotein; OLZ = olanzapine only; OLZ/A = olanzapine plus treatment algorithm A; OLZ/B = olanzapine plus treatment algorithm B.